Drugs, Industry, and Academia
- 20 June 2008
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 320 (5883) , 1563
- https://doi.org/10.1126/science.1161006
Abstract
This week, international academic and industry leaders, investors, and policy-makers participated in the Biotechnology Industry Organization's International Convention in San Diego, a reminder that prospects for new drugs seem bleak. Only 17 new molecular entities were approved by the U.S. Food and Drug Administration (FDA) in 2007, a fall from 53 in 1996. Coincident trends worsen the situation: a decline in prescription drug sales, the flight of investors, corporate layoffs, and pricing inequities in advanced economies that fuse with demands from poorer countries to gain cheap and immediate access to new drugs.Keywords
This publication has 0 references indexed in Scilit: